Jan Nolta
Overview
Explore the profile of Jan Nolta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
929
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le Blanc K, Dazzi F, English K, Farge D, Galipeau J, Horwitz E, et al.
Cytotherapy
. 2025 Jan;
PMID: 39864015
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought...
2.
Renesme L, Cobey K, Lalu M, Bubela T, Chinnadurai R, De Vos J, et al.
Cytotherapy
. 2024 Nov;
27(2):146-168.
PMID: 39580717
Background Aims: Despite promising results in pre-clinical studies, mesenchymal stromal cells (MSCs) face significant challenges in clinical translation. A scoping review by our group highlighted two key issues contributing to...
3.
Carter J, Halmai J, Waldo J, Vij P, Anguiano M, Villegas I, et al.
Stem Cells
. 2024 Oct;
43(1).
PMID: 39460716
Induced pluripotent stem cell (iPSC) models of neurodevelopmental disorders (NDDs) have promoted an understanding of commonalities and differences within or across patient populations by revealing the underlying molecular and cellular...
4.
Dave M, Dev A, Somoza R, Zhao N, Viswanath S, Mina P, et al.
NPJ Regen Med
. 2024 Jan;
9(1):6.
PMID: 38245543
Mesenchymal stem cells (MSCs) are novel therapeutics for the treatment of Crohn's disease. However, their mechanism of action is unclear, especially in disease-relevant chronic models of inflammation. Thus, we used...
5.
Dave M, Dev A, Somoza R, Zhao N, Viswanath S, Mina P, et al.
bioRxiv
. 2023 Jun;
PMID: 37292753
Objective: Mesenchymal stem cells (MSCs) are novel therapeutics for treatment of Crohn's disease. However, their mechanism of action is unclear, especially in disease-relevant chronic models of inflammation. Thus, we used...
6.
Viswanathan S, Le Blanc K, Ciccocioppo R, Dagher G, Filiano A, Galipeau J, et al.
Cytotherapy
. 2023 May;
25(8):803-807.
PMID: 37149800
The rapidly growing field of mesenchymal stromal cell (MSC) basic and translational research requires standardization of terminology and functional characterization. The International Standards Organization's (ISO) Technical Committee (TC) on Biotechnology,...
7.
Weiss D, Filiano A, Galipeau J, Khoury M, Krampera M, Lalu M, et al.
Cytotherapy
. 2022 Aug;
24(11):1071-1073.
PMID: 36028438
No abstract available.
8.
Hao D, Lu L, Song H, Duan Y, Chen J, Carney R, et al.
Theranostics
. 2022 Aug;
12(13):6021-6037.
PMID: 35966577
Although stem cell-derived extracellular vesicles (EVs) have remarkable therapeutic potential for various diseases, the therapeutic efficacy of EVs is limited due to their degradation and rapid diffusion after administration, hindering...
9.
Johnson S, Hoch J, Halabi W, Ko J, Nolta J, Dave M
Front Immunol
. 2022 Jul;
13:859954.
PMID: 35784367
Crohn's disease (CD) is an inflammatory bowel disease with increasing incidence and prevalence worldwide. Perianal fistulas are seen in up to 26% of CD patients and are often refractory to...
10.
Viswanathan S, Ciccocioppo R, Galipeau J, Krampera M, Le Blanc K, Martin I, et al.
Cytotherapy
. 2021 Jun;
23(12):1060-1063.
PMID: 34116944
The Cellular Therapy Coding and Labeling Advisory Group of the International Council for Commonality in Blood Banking Automation and the International Society for Cell & Gene Therapy mesenchymal stromal cell...